Dear Editor, Corneal fibrosis, a pathological scarring process, results from aberrant wound healing following trauma, infection, or surgery. It disrupts stromal transparency through excessive extracellular matrix deposition and myofibroblast activation, leading to visual impairment and blindness. Clinically, patients present with progressive loss of vision, photophobia, and ocular discomfort1. Current treatment modalities include topical corticosteroids, anti-fibrotic agents, and keratoplasty, which remains the gold standard for advanced cases. However, keratoplasty is limited by donor cornea shortages, graft rejection, and recurrence of fibrosis, underscoring the need for innovative alternatives such as gene editing approaches targeting transcriptional regulators like transforming growth factor-β induced factor homeobox 1 (TGIF1)2. TGIF1 is a transcriptional repressor implicated in modulating TGF-β signaling, a central pathway in fibrosis. CRISPR/Cas9-mediated TGIF1 editing functions by either silencing or activating TGIF1 expression in corneal stromal fibroblasts, thereby attenuating fibrotic gene cascades3,4. Its working principle relies on precise DNA cleavage and repair, enabling targeted modulation of fibrogenic pathways. Preclinical studies demonstrate efficacy in reducing alpha-smooth muscle actin (α-SMA) and collagen expression, markers of myofibroblast differentiation. Beyond corneal fibrosis, TGIF1 modulation holds therapeutic potential in hepatic fibrosis, pulmonary fibrosis, and renal scarring, where TGF-β signaling drives disease progression. In these conditions, prognosis improves when fibrotic remodeling is curtailed, highlighting the translational promise of TGIF1 editing5,6. Evidence from corneal models illustrates the therapeutic potential of TGIF1 editing. Tripathi et al demonstrated that CRISPR/Cas9-mediated TGIF1 knockout in human corneal stromal fibroblasts significantly reduced fibrotic gene expression, with α-SMA levels decreased by approximately 45% (P < 0.01) and collagen I expression reduced by 38% (P < 0.05), suggesting a viable anti-scarring strategy3. In parallel, studies in hepatic fibrosis models revealed that TGIF1 activation suppressed collagen deposition and improved histological outcomes, reinforcing its cross-organ anti-fibrotic role7. Together, these findings highlight TGIF1 as a versatile regulator of fibrosis, with corneal applications benefiting from insights gained in systemic fibrotic diseases. Despite promise, several hurdles limit clinical adoption. Gene-editing therapies remain resource-intensive, requiring advanced delivery systems such as viral vectors or nanoparticle carriers8. Off-target effects and incomplete editing efficiency pose risks of unintended mutations. In corneal applications, challenges include achieving uniform stromal penetration, avoiding immune activation, and ensuring long-term stability of edits9. Ethical and regulatory considerations in pediatric gene editing remain a barrier to clinical translation10. In conclusion, TGIF1-mediated gene editing represents a novel strategy for inhibiting corneal fibrosis and reducing reliance on keratoplasty. Future directions should prioritize multicenter validation, integration with proteomic profiling, and exploration of combination therapies to enhance efficacy5,6. Cost-effectiveness analyses and awareness campaigns will be essential to facilitate adoption in resource-limited settings. Clinical drives to evaluate safety and side effects will be critical to establish trust and optimize outcomes11.
Habib et al. (Tue,) studied this question.